SUMMARY A six month, double blind, crossover controlled trial of bezafibrate was conducted in 14 children with familial hypercholesterolaemia all of whom had a strong family history of early coronary heart disease. The bezafibrate was given twice daily in a dose of 10 to 20 mg/kg/day. The mean plasma total cholesterol concentration on bezafibrate was 22% lower than during the period on placebo and there was a moderate rise in high density lipoprotein cholesterol.
In the dominantly inherited condition of familial hypercholesterolaemia the risk of premature coronary heart disease is very high.' Reducing very high plasma concentrations of cholesterol (and low density lipoprotein) in middle aged men has been shown to lower the incidence of coronary heart disease. 2 To delay attempts at lowering lipids until middle age in this disorder will be too late for many patients, and it is expected that treatment will be of maximum benefit if started in childhood and continued throughout life.3 Dietary treatment alone is insufficient to achieve normal plasma cholesterol concentrations in some children with familial hypercholesterolaemia, and in the long term is ineffective in most because of poor compliance. 4 Cholestyramine is currently the drug of choice when additional treatment is required but we have shown that by the end of 8 years slightly less than half the children will still be taking this unpalatable drug.5 Other drugs, therefore, require evaluation in childhood.
Bezafibrate, an analogue of clofibrate, has been extensively used in the treatment of adults with various types of hyperlipoproteinaemia and has been shown to be effective in type Ila hyperlipoproteinaemia (the pattern in familial hypercholesterolaemia) in which it lowers both cholesterol and triglyceride concentrations.6 It has been well tolerated in adults without evidence of undesirable side effects for periods up to two years, and no evidence of long term toxicity has been found in studies in animals.7 Bezafibrate may, therefore, be a potentially useful drug for children with familial hypercholesterolaemia and we report the results of a double blind controlled study in children with this disorder. 34
Patients and methods
Fourteen children with heterozygous familial hypercholesterolaemia (eight girls and six boys, age range 4 to 15 years and including four sibling pairs) completed a six month, double blind crossover trial of bezafibrate and placebo. The diagnosis of familial hypercholesterolaemia had been established by finding a plasma total cholesterol concentration greater than 6-7 mmol/l (269 mg/100 ml) (the value found to result in minimal misclassification8), a type Ila pattern on lipoprotein electrophoresis, and normal fasting triglyceride (less than 1-5 mmol/19) in the patient, with either similar lipoprotein abnormalities in one of the parents, or where a parent had died of premature coronary heart disease, a similar lipid abnormality in another close relative. Before the trial all children had been treated by dietary measures (low saturated fat and increased polyunsaturated fat) which had proved inadequate to control plasma cholesterol concentrations, and they had therefore been given cholestyramine. All had refused to continue taking this drug after variable periods, and for at least three months before entry to the trial none had had any hypolipidaemic drug, and plasma cholesterol concentrations were unacceptably high (Table) . Although most children were still alleged by their parents to be taking a fat restricted diet, assessment by a dietitian indicated a mean total fat intake of 98 g/day (range 44 to 148 g). During the trial period the patients were asked not to change their diets but repeat assessments were not undertaken.
The trial had ethical committee approval, and informed consent was obtained. Active and placebo tablets were provided-the active tablets containing group.bmj.com on June 22, 2017 -Published by http://adc.bmj.com/ Downloaded from 100 mg bezafibrate. The dose of bezafibrate was 10 to 20 mg/kg/day given twice daily. The hospital pharmacist was responsible for randomly allocating the active (bezafibrate) tablets to either the first or second three month period; when there were two children in a family in the trial identical prescriptions were given to both to obviate the chance of confusion.
Blood were excreting bezafibrate in all samples of urine analysed during the active drug period and that no bezafibrate was detected in any sample collected during the placebo period. The patient in case 1 had no bezafibrate in his urine on two occasions during the active drug period, and it is noteworthy that it was only on the occasion when his urine contained bezafibrate that his plasma total cholesterol concentration was lower than the pre-trial or placebo period-6-09 mmol/l (236 mg/100 ml) compared with 7-4 and 7-6 mmol/l (287 and 294 mg/100 ml) respectively.
Other findings. In one child plasma alkaline phosphatase activity was high at the end of the third month on bezafibrate. At the time he had a mild intercurrent infection and values subsequently returned to normal. In another child there was a slight transient rise in alanine transaminase during the first two months on bezafibrate but values were normal at the end of the third month. In all other children, blood counts, liver function tests, and plasma electrolytes were normal. Growth was satisfactory throughout the trial and there were no reported clinical side effects. All children declared a strong preference for the tablets compared with their previous treatment with a resin.
Discussion
The mean reduction of plasma total cholesterol in the children in the present study (22%) is similar to that reported in adult studies, as is the rise in high density lipoprotein cholesterol (15%).6 "' There was considerable variation, however, in the response between individual patients, some showing little or no reduction in total cholesterol whereas others Double blind trial of bezafibrate in familial hypercholesterolaemia 37 showed a very considerable fall. The degree of response to bezafibrate could not be predicted by the initial values of total cholesterol before the trial, and in only one patient (case 1) is there evidence that non-compliance with drug treatment may have been responsible for a relatively poor response. The significantly higher mean total plasma cholesterol concentrations in the placebo period compared with the period before the trial cannot be explained. It is possible that there was some relaxation in the dietary regimen once the patients thought they were having alternative treatment; as dietary assessments were not repeated during the trial this cannot be confirmed. There was no correlation between the pre-trial fat intake and plasma cholesterol concentrations, nor did pre-trial fat intake correlate with the degree of change in either the bezafibrate or placebo period.
The dietary assessment carried out before the trial clearly indicated that few, if any, of the patients were complying with the degree of fat restriction advised and the efficacy of bezafibrate in our study must be judged against this background of a relatively high total fat intake; better results might well have been achieved had fat intake been lower, but as long term compliance with diet is so poor in children4 the present results are more indicative of what is likely to be achieved with continuation of bezafibrate treatment in the long term.
No clinical side effects attributable to bezafibrate occurred during the short period of study, and all children volunteered that they preferred taking bezafibrate tablets to cholestyramine. In view of the transient rise in plasma alkaline phosphatase in one patient (possibly attributable to an intercurrent illness) and in alanine transaminase (unexplained) in another patient, regular monitoring of liver function should probably be undertaken in any children on long term treatment.
In conclusion, our study has shown that bezafibrate can result in useful lowering of the plasma total cholesterol concentration, coupled with a moderate rise in the plasma high density lipoprotein cholesterol concentration, in children with familial hypercholesterolaemia. Because the long term safety of this drug has not yet been established in prospective trials in adults we would not recommend it for the initial treatment of children with familial hypercholesterolaemia. Nevertheless, for those children who cannot take cholestyramine, and whose risk of early coronary heart disease is high as judged by family history, it may have a useful role to play in treatment, though careful monitoring will be required.
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